Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
about
Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspectiveEffective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimineImpact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysisAdjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot studyAntituberculosis drug resistance patterns in two regions of Turkey: a retrospective analysisThe characterization of upper-room ultraviolet germicidal irradiation in inactivating airborne microorganisms.Crystal structure of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase IIIThe crystal structure of Mycobacterium tuberculosis alkylhydroperoxidase AhpD, a potential target for antitubercular drug designThe mechanism of Mycobacterium tuberculosis alkylhydroperoxidase AhpD as defined by mutagenesis, crystallography, and kineticsGram-positive DsbE proteins function differently from Gram-negative DsbE homologs. A structure to function analysis of DsbE from Mycobacterium tuberculosisAn Extracellular Disulfide Bond Forming Protein (DsbF) from Mycobacterium tuberculosis: Structural, Biochemical, and Gene Expression AnalysisThe antituberculosis drug ethionamide is activated by a flavoprotein monooxygenaseTreatment of tuberculosis in HaitiKanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium Growth Indicator Tube and a colorimetric methodMoxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosisCost-effectiveness of treating multidrug-resistant tuberculosisFeasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the PhilippinesOutcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosisProtection elicited by two glutamine auxotrophs of Mycobacterium tuberculosis and in vivo growth phenotypes of the four unique glutamine synthetase mutants in a murine modelAll four Mycobacterium tuberculosis glnA genes encode glutamine synthetase activities but only GlnA1 is abundantly expressed and essential for bacterial homeostasisIdentification and characterization of a regulatory sequence recognized by Mycobacterium tuberculosis persistence regulator MprAExposure to antibiotics induces expression of the Mycobacterium tuberculosis sigF gene: implications for chemotherapy against mycobacterial persistorsConstruction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate sigma factor gene, sigF.Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV regionAre we doing enough to stem the tide of acquired MDR-TB in countries with high TB burden? Results of a mixed method study in Chongqing, ChinaTreatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication.Tuberculosis in Thailand.Identification of murine H2-Dd- and H2-Ab-restricted T-cell epitopes on a novel protective antigen, MPT51, of Mycobacterium tuberculosis.Treatment of isoniazid-resistant pulmonary tuberculosis.Identification of an HLA-A*0201-restricted T-cell epitope on the MPT51 protein, a major secreted protein derived from Mycobacterium tuberculosis, by MPT51 overlapping peptide screening.Primary antimicrobial resistance among Mycobacterium tuberculosis isolates from HIV seropositive and HIV seronegative patients in Dar es Salaam Tanzania.First insights into the genetic diversity of Mycobacterium tuberculosis isolates from HIV-infected Mexican patients and mutations causing multidrug resistance.Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition.Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosisThe Rate of Drug-Resistant Tuberculosis in Korean Children and Adolescents Since 2007.Epidemiology and treatment of multidrug resistant tuberculosisSystematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from SpainAntimicrobial resistance in developing countriesTuberculosis in prisons in countries with high prevalence.
P2860
Q24535810-4F7DB3BC-4A45-480B-828D-6E0F8F00D6A4Q24550649-2233E6E1-B361-44F8-AB3F-F9458C88A259Q24554274-F2F0EA5C-87B2-4B17-9BD3-3A65ACDB8692Q24795200-A75310AF-BC2D-4C9D-97A4-0299491F8401Q24799126-EADA21BB-C9D2-4EC8-8EE1-072CCDDFDEA8Q24815454-524DCBB7-4FDC-4F8E-9681-D84DB7B76DCBQ27630901-148041FD-328E-4087-93CE-ED11BC82EE95Q27638528-BC968816-739F-47B2-9361-2C8D04539841Q27641305-70BED729-2101-4BEE-AA10-CF725E4F90BDQ27642487-5F7C4796-3694-4CEF-B75C-B95FA1FDD14EQ27658897-F7AB0BB1-9CA0-4494-9630-03AE6C595C96Q28217168-B92A277E-BE53-4BF4-965E-27D170EAD9F0Q28360407-9F138161-78C2-4D75-A07F-F397C615B43DQ28365220-D5C06027-E258-44BC-AE17-54BC3F76120DQ28369466-3B0EC584-1E32-482B-AE7C-81DDC76B2F16Q28469015-4B8B3898-D2AB-49F0-86DD-2C5E25293EB9Q28469046-2B965BBE-50FA-40D8-8106-0DCF1E189120Q28471986-C0B43796-9859-449F-903B-9C51DDA9570EQ28486534-325CE96F-B08A-4105-96B8-A75B4851DA7BQ28486561-7B4278F7-449D-4665-ABBE-64F1A90A3211Q28486912-72FCAB39-0EBD-493A-B8F6-AF235549D607Q28487060-5B634221-8A2D-4E13-9376-1B25C6FFD6ACQ28487440-A3D959F0-D17D-4F87-88DB-A8D10121183EQ28534875-3ED81B96-0A3B-4749-8AF0-D2A24E4CCEF4Q28539576-130919B0-1A20-4EA5-9B7A-DCE1597AE3EAQ30325785-67DC7876-FB30-49C8-923D-443D2056705DQ30328025-99ED2415-A1B7-4637-8203-142FEB989E8BQ31080718-98C7426B-06B4-4F58-9274-BECA7BFF02CFQ33315736-E3725F83-49C8-4D8F-9E6F-86B5CE3917B1Q33315752-A7EBCED7-E53E-430B-BA87-02EF5D5746BAQ33360959-A8D37717-177F-4C70-9CFC-5873E63A2796Q33541750-029CF8C6-D377-451B-90C5-2171B5590C7BQ33558303-223471ED-D9B3-49F7-A55E-03F24801C2A4Q33601443-890AF297-BDF6-439D-8F10-5608DB58F982Q33630442-D8B7DB33-1ED4-4CBF-B18F-565E338C7C0AQ33661497-914D82A3-8526-4F5F-BA48-03F024E0155AQ33710690-56DC3B50-5C96-48A6-A338-76F5407B9545Q33752939-D09006E6-03F9-44D2-8633-208AF17563ACQ33791783-58E5B794-CA9E-47A1-B9AD-53778EF6215CQ33799879-B29ED859-E0F6-4167-BC96-C2E637CEB9A5
P2860
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Global surveillance for antitu ...... Drug Resistance Surveillance.
@en
Global surveillance for antitu ...... Drug Resistance Surveillance.
@nl
type
label
Global surveillance for antitu ...... Drug Resistance Surveillance.
@en
Global surveillance for antitu ...... Drug Resistance Surveillance.
@nl
prefLabel
Global surveillance for antitu ...... Drug Resistance Surveillance.
@en
Global surveillance for antitu ...... Drug Resistance Surveillance.
@nl
P2093
P1476
Global surveillance for antitu ...... Drug Resistance Surveillance.
@en
P2093
Lambregts-van Weezenbeek CS
Pablos-Méndez A
Raviglione MC
P304
P356
10.1056/NEJM199806043382301
P407
P577
1998-06-01T00:00:00Z